The Company is a clinical-stage drug development company that discovers and develops novel, small molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases.


Updates from The Motley Fool

Latest updates on Rigel Pharmaceuticals from Fool.com.  The Fool has written over 100 articles on Rigel Pharmaceuticals.
This Week in Biotech

A mammoth buyout, positive clinical data, a new drug filing, and yet another disappointment for o...

This Week in Biotech

An FDA approval, the possibility of a small-cap biotech buyout, and updated clinical info from tw...



Stock Performance

View Interactive RIGL Charts
Sponsored by

Key Data Points

Primary metrics and data points about Rigel Pharmaceuticals.
Current Price: $2.77
Prev Close: $2.72
Open: $2.71
Bid: $2.60
Ask: $2.87
Day's Range: $2.69 - $2.81
52wk Range: $1.90 - $4.38
Volume: 871,520
Avg Vol 1,379,605
Market Cap: $339M
P/E (ttm): -3.73
EPS (ttm): ($0.73)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Rigel Pharmaceuticals.
CAPS Rating 5 out of 5
 
153 Outperform
56 Underperform
CAPS All Stars
 
33 Outperform
15 Underperform

How do you think Rigel Pharmaceuticals will perform against the market?



You pick for Rigel Pharmaceuticals is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Raul Rodriguez, CEO

100% Approve

Based on 1 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Rigel Pharmaceuticals.

The Company is a clinical-stage drug development company that discovers and develops novel, small molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers